Table 1 Characteristics of trials in the Gastrointestinal and Lymphoma Unit (n = 36)

Study type

 CTIMP

24 (67 %)

 Non-CTIMP

9 (25 %)

 Pre-screening

3 (8 %)

Sponsor

 Royal Marsden

9 (25 %)

 Other academic institution

11 (31 %)

 Pharmaceutical company

16 (44 %)

Phase

 I

2 (6 %)

 II

10 (28 %)

 II/III

2 (6 %)

 III

13 (36 %)

 Not applicable

9 (25 %)

Trial setting

 Neoadjuvant

3 (8 %)

 Adjuvant

3 (8 %)

 Advanced

16 (44 %)

 Any

5 (14 %)

 Lymphoma^a

9 (25 %)

Randomised trial

 Yes

20 (56 %)

 No

16 (44 %)

Molecular screening

 Yes

10 (28 %)

 No

26 (72 %)

Number of PIS (e.g. separate pharmacodynamics or imaging sub-studies)

 1

20 (56 %)

 2

11 (31 %)

 3

4 (11 %)

 5

1 (3 %)